Lochmüller Hanns, Aymé Ségolène, Pampinella Francesca, Melegh Béla, Kuhn Klaus A, Antonarakis Stylianos E, Meitinger Thomas
1 Institute of Human Genetics, Newcastle University , Newcastle upon Tyne, United Kingdom .
Biopreserv Biobank. 2009 Sep;7(3):155-6. doi: 10.1089/bio.2010.7302.
Biobanking is of high importance for research in rare diseases. There are >6,000 rare diseases with at least 30 million people affected in the European Union (EU). The European Commission (EC) has prioritized rare diseases in recent health and research programs. The rarity and diversity of rare diseases and their associated biomaterials harbor specific challenges and opportunities for biobanking requiring transnational collaboration and harmonization. Small collections or even individual samples may be extremely precious for research. Importantly, most rare disease biobanks work through the active participation of patients and patient organizations, and share benefits with them. This article gives recommendations related to rare disease biobanking reflecting consensus of an expert working group of the Biobank and Biomolecular Research Infrastructure program at a meeting in Munich on December 17-18, 2008.
生物样本库对于罕见病研究至关重要。在欧盟,有超过6000种罕见病,至少3000万人受其影响。欧盟委员会在近期的健康和研究项目中已将罕见病列为优先事项。罕见病及其相关生物材料的罕见性和多样性给生物样本库带来了特定挑战和机遇,这需要跨国合作与协调。少量样本甚至单个样本对于研究可能极其珍贵。重要的是,大多数罕见病生物样本库通过患者及患者组织的积极参与开展工作,并与他们共享收益。本文给出了与罕见病生物样本库相关的建议,这些建议反映了生物样本库和生物分子研究基础设施项目专家工作组在2008年12月17 - 18日于慕尼黑召开的一次会议上达成的共识。